Genmab — Januar 2023
-
Mornings. Its difficult to disagree that point of view
-
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023 https://www.proinvestor.com/investornyt/931259/3-reasons-why-johnson-amp-johnson-stock-could-rebound-after-a-bad-start-in-2023
-
from Scancell: Genmab [] has accelerated one of our antibodies into development - I take that as that they have identified one and started working seriously on it https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/interim-report-31-october-2022.pdf
-
En såkaldt kollektiv afklapsning hele vejen rundt
-
Jeg forstår så ikke helt, hvorfor C25 skal have så store klø i.f.t. resterende lande i Europa.
-
Sundhed faldt i US i går. Det fortsatte i DK i dag i C25, hvor sektoren med især Novo fylder meget. Læg hertil det aktiespecifikke fald i f.eks. Maersk og Netcompany.
-
Det er korrekt, @Helge. Og du hygger dig vel, lige idag, med dine grønne laks
-
Onsdagens aktier: Svag prognose kostede Netcompany dyrt https://www.proinvestor.com/investornyt/931480/onsdagens-aktier-svag-prognose-kostede-netcompany-dyrt
-
Godmorgen
-
Teprotumumab for the treatment of thyroid eye disease https://www.tandfonline.com/doi/abs/10.1080/14712598.2023.2172328?src=&journalCode=iebt20
-
Godt entry niveau for den langsigtede investor. 4-10 mdr. Kortsigt risiko at kursen kan falde ned til 2400. https://www.proinvestor.com/boards/107914/$/109852
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind